More than a year after Abbott and Alere agreed to merge, the lawsuits have been closed and the marriage is back on. The contract was renegotiated, of course.
Acquisitions of laboratories, imaging and dialysis centers declined in 2016, as each of the sectors faced headwinds.
Medical Devices is finishing the year on a high note. In fact, as of December 29, 2016, deal volume reached 113 transactions, equal to 2015’s total. Deal value topped off at $61.3 billion, a 111% increase from last year’s total of $29.1 billion.
It’s been a busy year for healthcare deal making. As of December 2, the combined total spending was $239.1 billion, going to finance 1,419 transactions. That’s 40% behind the $400 billion spent in all of 2015, but just 7% behind last year’s deal volume of 1,520 deals.
It’s been a busy year for mergers and acquisitions in the Medical Device sector. Through December 2, 108 transactions have been announced in 2016, compared with 113 in all of 2015. Target companies specializing in cardiovascular devices make up a small percentage of those deals, but tend to post large prices. So far, $32.8 billion […]
Only a few weeks into the fourth quarter, and five medical device deals have been announced, putting the year’s total at 95. Abbott (NYSE: ABT) and St. Jude Medical’s (NYSE: STJ) $1.12 divestiture of certain vascular closure and electrophysiology assets is among these five October deals, and the only one to disclose a price. On October […]
We’re still in preliminary territory, so don’t bank on this yet. Health care M&A hit 120 deals for the month of April 2016, down 12% versus the previous month’s 136 deals, but 7% better than the same month a year ago. Long-term care deals led the transaction activity with 21 deals (18% of the total), […]
Medical device deals are back in fashion. In the first four months of 2016, 41 deals were announced in this sector, compared with just 30 for the comparable time period in 2015. Spending on deals in this sector has already hit $42.7 billion, compared with $5.7 billion in the first four months of 2015. The largest by far this […]
Johnson & Johnson (NYSE: JNJ) announced the restructuring of its medical devices business on January 19, 2016. Its 8K filing noted pre-tax restructuring charges of $2.0 billion to $2.4 billion, expected to be incurred this year, as well as a Q4:15 charge of approximately $600 million. About 4% to 6% of the division’s global workforce will get […]